KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+3.72%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$314M
AUM Growth
+$314M
(+3.8%)
Cap. Flow
+$17.4M
Cap. Flow
% of AUM
5.54%
Top 10 Holdings %
Top 10 Hldgs %
96.81%
Holding
15
New
1
Increased
9
Reduced
4
Closed
1
Top Buys
| 1 |
Biogen
BIIB
|
$18M |
| 2 |
Cardinal Health
CAH
|
$10.5M |
| 3 |
Exelixis
EXEL
|
$4.93M |
| 4 |
Vanda Pharmaceuticals
VNDA
|
$3.09M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$348K |
Top Sells
| 1 |
McKesson
MCK
|
$17.3M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$1.84M |
| 3 |
Kodiak Sciences
KOD
|
$656K |
| 4 |
United Therapeutics
UTHR
|
$172K |
| 5 |
Assembly Biosciences
ASMB
|
$21K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$19.4B
| $49.3M | 15.7% | 184,648 +67,400 | +57% | +$18M |
|
|
2
United Therapeutics
UTHR
$13.8B
| $42M | 13.36% | 200,407 -821 | -0.4% | -$172K |
|
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $41.9M | 13.36% | 60,889 +505 | +0.8% | +$348K |
|
4
Alkermes
ALKS
$4.78B
| $31.5M | 10.04% | 1,411,682 +13,523 | +1% | +$302K |
|
|
5
Enanta Pharmaceuticals
ENTA
$180M
| $30.6M | 9.73% | 589,360 -35,408 | -6% | -$1.84M |
|
6
Embecta
EMBC
$847M
| $29.5M | 9.39% | 1,024,200 +7,006 | +0.7% | +$202K |
|
|
7
Exelixis
EXEL
$10.1B
| $28.6M | 9.09% | 1,821,475 +314,590 | +21% | +$4.93M |
|
|
8
Cardinal Health
CAH
$35.5B
| $22.5M | 7.15% | 336,742 +157,903 | +88% | +$10.5M |
|
|
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $17.4M | 5.54% | 580,793 +269 | +0% | +$8.07K |
|
|
10
McKesson
MCK
$85.4B
| $10.8M | 3.45% | 31,913 -50,981 | -62% | -$17.3M |
|
|
11
Kodiak Sciences
KOD
$478M
| $3.63M | 1.16% | 469,388 -84,804 | -15% | -$656K |
|
|
EGRX
12
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.2M | 1.02% | 121,083 +69 | +0.1% | +$1.82K |
|
|
13
Vanda Pharmaceuticals
VNDA
$279M
| $3.09M | 0.98% | +312,299 | New | +$3.09M |
|
14
NextCure
NXTC
$13.5M
| $86K | 0.03% | 31,298 +299 | +1% | +$822 |
|
|
15
Assembly Biosciences
ASMB
$190M
| – | – | -9,985 | Closed | -$21K |
|